ZERON BIO signed an MOU with 3DMedivision to advance into domestic and overseas veterinary markets based on PDRN

ZERON BIO, a PDRN-based raw material drug company, announced on the 27th that it has signed a strategic MOU with 3DMedivision to enter the domestic and foreign veterinary market.

ZERON BIO plans to join hands with 3DMedivision, a company specializing in medical edutech, to launch joint research to enter the domestic and foreign veterinary market. Based on PDRN-based pharmaceutical technology developed by ZERON BIO with its own technology, it will jointly target the domestic and foreign veterinary markets by utilizing the veterinary infrastructure owned by 3DMedivision.

PDRN is a nucleic acid substance extracted from salmon sperm or sperm, and is widely used as filler, pain injections, and eye drops in the phosphorus market due to its excellent regenerative effect. ZERON BIO will start producing pain injections, eye drops, and fillers and start selling them in earnest next year.

Until now, PDRN has not been used in the veterinary market due to high prices, but ZERON BIO has developed mass production technology, enabling it to enter the veterinary market. Based on this, ZERON BIO expects to maximize synergy with 3DMedivision, the No. 1 medical edutech company in the veterinary field.

3DMediVision established a 200-pyeong training center in Songdo last year. There are 15 beds, surgical instruments, and 3D filming equipment installed. In addition, next to the laboratory, 132 people can watch videos in real time and share their opinions, making it a leading company in the domestic and foreign veterinary education market.

Kim Ki-jin, CEO of 3DMediVision, said, "This agreement has created a foundation for providing high-quality veterinary services," adding, "We have prepared another revenue generation source through entering the animal market using PDRN."

Kim Deok-gyu, CEO of ZERON BIO, also said, "Based on 3DMedivision's excellent infrastructure, we will be able to pioneer another market using PDRN," adding, "We will try to contribute to the veterinary market by making various treatments through PDRN in the future."

[Money Today startup media platform "Unicorn Factory"]

Sources : https://news.mt.co.kr/mtview.php?no=2022122713523964732 (Kr)